Balyasny Asset Management
CAPR icon

Balyasny Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Balyasny Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,000
Closed -$1.39M – 2952
2025
Q2 		$1.39M Buy
+140,000
New +$1.48M ﹤0.01% 1911

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management's CAPR Position: Q1 2026 in Review

Balyasny Asset Management reduced its Capricor Therapeutics (CAPR) stake by 16% in Q1 2026, selling an estimated $1.49M and leaving 297,123 shares worth $9.03M. The position accounts for 0.01% of the portfolio, ranked #1078.

Balyasny Asset Management first reported a position in CAPR in Q1 2024 and has held it in 4 quarters since. The position peaked at $10.2M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Balyasny Asset Management held 297,123 shares of Capricor Therapeutics worth $9.03M as of Q1 2026.
  • Balyasny Asset Management sold 55,875 Capricor Therapeutics shares in Q1 2026, an estimated $1.49M.
  • Capricor Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1078 holding.
  • Balyasny Asset Management first reported a position in Capricor Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Balyasny Asset Management's Capricor Therapeutics position peaked at $10.2M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.